# Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer

> **NCT05288777** · PHASE2,PHASE3 · RECRUITING · sponsor: **University of Virginia** · enrollment: 45 (estimated)

## Conditions studied

- Breast Cancer
- Breast Cancer Stage I
- Breast Cancer Stage II
- Breast Cancer Stage III

## Interventions

- **DRUG:** T-DM1
- **DRUG:** Capecitabine
- **RADIATION:** External Beam Radiation Therapy 0
- **RADIATION:** External Beam Radiation Therapy 1

## Key facts

- **NCT ID:** NCT05288777
- **Lead sponsor:** University of Virginia
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-07-11
- **Primary completion:** 2028-12
- **Final completion:** 2029-12
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2025-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05288777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05288777, "Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT05288777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*